About
Plakous Therapeutics develops human placental extract (HPE) biologics aimed at treating inflammation-driven diseases such as necrotizing enterocolitis and pediatric malabsorption, supported by rare pediatric and orphan drug designations and NIH Phase IIB SBIR funding.
Explore Plakous Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.